Hemogenyx Pharmaceuticals PLC Grant of Options (8331W)

TIDMHEMO

RNS Number : 8331W

Hemogenyx Pharmaceuticals PLC

21 August 2020

21 August 2020

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Grant of Options

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company ("Share Options") to the Company's co-founder and CEO Dr Vladislav Sandler.

The details of the Share Options granted are set out below:

 
 Name            Position    Number      Exercise   Vesting Date   Expiry Date 
                              of Share    Price 
                              Options     (pence) 
                              Granted 
 Dr Vladislav 
  Sandler        CEO         5,000,000   7          Immediate      19 August 2025 
                ----------  ----------  ---------  -------------  --------------- 
 

Following the grant of the Share Options there are, in aggregate, 42,465,786 ordinary shares of 1p each in the Company under option held by directors, employees and members of the Scientific Advisory Board of the Company, representing 9.79% of the issued ordinary share capital of the Company.

Enquiries:

 
 Hemogenyx Pharmaceuticals plc           https://hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive 
  Officer & Co-Founder                   [e-mail] 
 Peter Redmond, Director                 [e-mail] 
 
                                         Tel: [phone] 
 SP Angel Corporate Finance LLP           0470 
 Matthew Johnson, Vadim Alexandre, 
  Soltan Tagiev 
 
                                         Tel: [phone] 
 Peterhouse Capital Limited               0930 
 Lucy Williams, Duncan Vasey, Charles 
  Goodfellow 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):

 
 1.   Details of PDMR/person closely associated with them 
 a)   Name                         Dr Vladislav Sandler 
     ---------------------------  -------------------------------------- 
 b)   Position/status              CEO, Executive Director 
     ---------------------------  -------------------------------------- 
 c)   Initial notification/        Initial notification 
       amendment 
     ---------------------------  -------------------------------------- 
 2.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ------------------------------------------------------------------- 
 a)   Description of               Options over ordinary shares of 1p 
       the financial                of Hemogenyx Pharmaceuticals plc 
       instrument                   Identification code GB00BYX3WZ24 
     ---------------------------  -------------------------------------- 
 b)   Nature of the                Grant of options 
       transaction 
     ---------------------------  -------------------------------------- 
 c)   Price(s) and                  Price(s)    Volume(s) 
       volume(s)                     GBP0.07     5,000,000 
                                                ---------- 
     ---------------------------  -------------------------------------- 
 d)   Aggregated information        Price(s)          Volume(s) 
       - Aggregated                  N/A - variable    5,000,000 
       volume                                         ---------- 
       - Price 
     ---------------------------  -------------------------------------- 
 e)   Date of the transaction      20/08/2020 
     ---------------------------  -------------------------------------- 
 f)   Place of the                 Outside of a trading venue 
       transaction 
     ---------------------------  -------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHDZGZRRMRGGZG

(END) Dow Jones Newswires

August 21, 2020 04:52 ET (08:52 GMT)